Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT

作者：Donal P. McLornan, Vittoria Carolina Malpassuti, Anne Lippinkhof‐Kozijn, Victoria T. Potter, Dietrich Wilhelm Beelen, Donald Werner Bunjes, Henrik Sengeloev, Aleksandar Radujkovic, Jakob Robert Passweg, Yves Chalandon, Nicolaus Martin Kröger, Gerald Georg Wulf, Jan‐Erik Johansson, Fabio Ciceri, Martin Bornhäuser, Ernst Holler, Blandine Guffroy, Sonja Martin, Andreas Neubauer, Martin Gramatski, Marie Robin, Simona Iacobelli, Patrick John Hayden, Juan Carlos Hernández‐Boluda, Tomasz Czerw, Ibrahim Yakoub‐Agha · 发表于：British Journal of Haematology · 年份：2020 · DOI：10.1111/bjh.16537 · 被引用次数：6 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Acute Myeloid Leukemia Research、Chronic Myeloid Leukemia Treatments

Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.